April 6, 2022 07:25 AM EDT
FDA+
Coronavirus

FDA halts the use of GSK's Covid-19 drug com­plete­ly as BA.2 sub­vari­ant blan­kets the coun­try

Zachary Brennan

Senior Editor

It on­ly took the Omi­cron BA.2 sub­vari­ant three busi­ness days to go from shut­ting down Glax­o­SmithK­line and Vir Biotech­nol­o­gy’s Covid-19 treat­ment sotro­vimab in 22 states …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

A service from the Financial Times